QQQ   289.89 (-0.43%)
AAPL   136.75 (-2.89%)
MSFT   252.52 (-0.61%)
FB   191.36 (-0.46%)
GOOGL   2,205.65 (-1.45%)
AMZN   2,152.15 (+0.46%)
TSLA   707.89 (-0.27%)
NVDA   172.10 (+1.61%)
BABA   87.99 (+0.78%)
NIO   16.59 (+4.80%)
AMD   97.58 (+1.35%)
CGC   5.90 (+5.55%)
MU   69.67 (-1.94%)
T   20.12 (-0.54%)
GE   75.55 (+0.47%)
F   12.88 (+0.78%)
DIS   103.48 (-0.79%)
AMC   12.75 (-0.08%)
PFE   50.31 (-0.18%)
PYPL   80.61 (+4.44%)
NFLX   183.60 (+3.62%)
QQQ   289.89 (-0.43%)
AAPL   136.75 (-2.89%)
MSFT   252.52 (-0.61%)
FB   191.36 (-0.46%)
GOOGL   2,205.65 (-1.45%)
AMZN   2,152.15 (+0.46%)
TSLA   707.89 (-0.27%)
NVDA   172.10 (+1.61%)
BABA   87.99 (+0.78%)
NIO   16.59 (+4.80%)
AMD   97.58 (+1.35%)
CGC   5.90 (+5.55%)
MU   69.67 (-1.94%)
T   20.12 (-0.54%)
GE   75.55 (+0.47%)
F   12.88 (+0.78%)
DIS   103.48 (-0.79%)
AMC   12.75 (-0.08%)
PFE   50.31 (-0.18%)
PYPL   80.61 (+4.44%)
NFLX   183.60 (+3.62%)
QQQ   289.89 (-0.43%)
AAPL   136.75 (-2.89%)
MSFT   252.52 (-0.61%)
FB   191.36 (-0.46%)
GOOGL   2,205.65 (-1.45%)
AMZN   2,152.15 (+0.46%)
TSLA   707.89 (-0.27%)
NVDA   172.10 (+1.61%)
BABA   87.99 (+0.78%)
NIO   16.59 (+4.80%)
AMD   97.58 (+1.35%)
CGC   5.90 (+5.55%)
MU   69.67 (-1.94%)
T   20.12 (-0.54%)
GE   75.55 (+0.47%)
F   12.88 (+0.78%)
DIS   103.48 (-0.79%)
AMC   12.75 (-0.08%)
PFE   50.31 (-0.18%)
PYPL   80.61 (+4.44%)
NFLX   183.60 (+3.62%)
QQQ   289.89 (-0.43%)
AAPL   136.75 (-2.89%)
MSFT   252.52 (-0.61%)
FB   191.36 (-0.46%)
GOOGL   2,205.65 (-1.45%)
AMZN   2,152.15 (+0.46%)
TSLA   707.89 (-0.27%)
NVDA   172.10 (+1.61%)
BABA   87.99 (+0.78%)
NIO   16.59 (+4.80%)
AMD   97.58 (+1.35%)
CGC   5.90 (+5.55%)
MU   69.67 (-1.94%)
T   20.12 (-0.54%)
GE   75.55 (+0.47%)
F   12.88 (+0.78%)
DIS   103.48 (-0.79%)
AMC   12.75 (-0.08%)
PFE   50.31 (-0.18%)
PYPL   80.61 (+4.44%)
NFLX   183.60 (+3.62%)

Bank of America (NYSE: BAC) Among The Best Of The Bunch

Tuesday, January 12, 2021 | Sam Quirke
Bank of America (NYSE: BAC) Among The Best Of The BunchAs most equities spent Monday’s session taking a breather after finishing at all time highs last week, shares of Bank of America (NYSE: BAC) found themselves up 1.6% and closing at a post-COVID high. They’ve been on a solid run for the past couple of months, easily outpacing the S&P 500 index since May for a 54% run to the latter’s 32%.

They’ve taken some solid momentum with them into 2021 and investors will be expecting them to complete the recovery of last year’s crash in the coming months. Were they to do this, it would also put them at a post-2008 high, which is a nice carrot to have dangling in front of management. Based on recent updates, you’d find it hard to bet against them doing so.

Upgraded By Peer

Bank of America’s financial neighbor Citigroup (NYSE: C) started the week off on a positive note for them with an upgrade out of the blocks on Monday. They moved Bank of America shares from Neutral to a Positive rating and upped their price target from $31 to $37, which suggests there’s still upside of more than 10% to be had from Monday’s close.

Citi’s move comes less than a week after Wolfe Research also upped their rating on Bank of America to Outperform. Analyst Steven Chuba sees them being the strongest of the big financials and in particular are well "insulated" from capital markets normalization. What seems to be underpinning these moves is a steady uptick in the 10-year Treasury yield, which only last week climbed above 1% for the first time since last year’s crash. A steepening yield curve is considered a major tailwind for banks, which will be a relief for investors as they’ve had to plod along as best they can for some time without it now.


Additional macro based tailwinds such as a weakening dollar are also starting to gather some pace. USD/GBP is down more than 6% since September, USD/EUR is down nearly 5% since November, while the USD/JPY is down that much since June. These are all bullish signs for Bank of America investors, as historically a weaker dollar has been a boon for bank stocks. It tends to lead to a steepening yield curve (see above) and allows lenders to get cash at low, short-term rates and then lend it out to borrowers at higher, longer-term rates.

Macro Tailwinds

This trend has been a long time coming after the greenback soared against the other majors last March, as investors fled equities for safer assets. Indeed, it’s a testament to Bank of America that they managed to close last year out at the highs that they did, outpacing the S&P 500 while they did it, while they lacked their traditional tailwinds for most of it.

The recent rollout of COVID vaccines has done much to assuage investors’ fears and regulators’ worries about the heavyweights of Wall Street’s ability to ride out the pandemic. At the lows of last year, they’d been asked to shore up their bad loan provisions while share buyback programs had been banned. The unwinding of both of these restrictions in the past month or so has done a lot to improve the outlook for banks in 2021 and we’re seeing that reflected in recent share price action.

All the factors are now in place for 2021 to be a banner year for them and there’s every reason to think that Bank of America will soon close the 8% gap to get back to their decade highs.

Bank of America (NYSE: BAC) Among The Best Of The Bunch

Should you invest $1,000 in Bank of America right now?

Before you consider Bank of America, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bank of America wasn't on the list.

While Bank of America currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Bank of America (BAC)
3.1048 of 5 stars
$34.32-1.6%2.45%9.81Buy$50.38
Citigroup (C)
3.4416 of 5 stars
$49.82+1.0%4.09%5.88Hold$70.48
Compare These Stocks  Add These Stocks to My Watchlist 

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.